Pharmacy has a prominent role in the supply and provision of biosimilar medicines, and the profession has been slow to come to terms with this. Is the situation now changing? In 2015, the Pharmaceutical Benefits Advisory Committee (PBAC) made the decision to consider the marking as equivalent—or “a” flagging—of biosimilar medicines and their reference products.
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.